The Food and Drug Administration (FDA) reviews brand-name testosterone before it is sold. Compounded testosterone is sold without that review. At Longevity Benchmark, we examine the regulatory filings and clinical practice guidelines behind hormone therapies to show what each product classification means for patient care.
Men considering testosterone replacement therapy (TRT) are often presented with choices between commercial brand-name pharmaceuticals and custom formulations prepared by compounding pharmacies. That choice influences manufacturing oversight, adverse-event tracking, and how quickly new clinical safety findings reach patient paperwork.
The Verdict
Brand-Name Testosterone vs Compounded Testosterone
| Attribute | Brand-name testosterone | Compounded testosterone |
|---|---|---|
| FDA approval status | Approved by the FDA for specific medical indications | Not approved by the FDA |
| Premarket safety and quality review | FDA verifies safety, effectiveness, and quality before marketing | FDA does not verify safety, effectiveness, or quality before marketing |
| Manufacturing standards | Subject to federal Current Good Manufacturing Practice (CGMP) rules | 503A pharmacies are exempt from CGMP; 503B outsourcing facilities must follow CGMP |
| Facility oversight and inspection | Routine FDA facility inspections and federal compliance reviews | State boards of pharmacy oversee 503A pharmacies; FDA inspects 503B facilities on a risk-based schedule |
| Adverse-event reporting obligations | Mandatory federal adverse-event reporting required for manufacturers | No comparable federal reporting obligation historically applied to compounding pharmacies |
| Class-wide FDA label updates | Mandatory label changes apply directly to all commercial packaging | No FDA-reviewed label exists, so updates do not automatically reach product paperwork |
| Formulation flexibility | Fixed commercial doses, standard delivery bases, and set concentrations | Custom strengths, alternative delivery bases, and personalized concentrations |
| Controlled substance schedule | Schedule III controlled substance requiring a registered prescriber | Schedule III controlled substance requiring a registered prescriber |
| Required patient monitoring | Baseline and periodic hemoglobin and hematocrit testing | Baseline and periodic hemoglobin and hematocrit testing |
| Monthly drug cost ranges | Injections $30 to $100 monthly; gel $40 to $300 monthly; pellets $500 to $1,000 per insertion in our published ranges, checked September 2026 | Injections $30 to $100 monthly; cream $40 to $300 monthly; pellets $500 to $1,000 per insertion in our published ranges, checked September 2026 |
The Regulatory Difference Stated Plainly
Brand-name testosterone products must complete the formal FDA approval process before reaching patients, whereas compounded testosterone is exempt from premarket evaluation. Under federal rules detailed in the FDA compounding guidance, the agency does not verify the safety, effectiveness, or manufacturing quality of compounded medications prior to sale. This lack of premarket review does not make compounded testosterone illegal.
State and federal laws permit licensed pharmacies to prepare customized medications for individual patients with specific medical needs. However, the FDA warns that unnecessary use of compounded drugs can expose patients to health risks when an approved commercial alternative exists. Commercial products undergo extensive clinical trials and batch verification before reaching pharmacies. Compounded products bypass those premarket checks entirely.
503A Pharmacies and 503B Outsourcing Facilities
The regulatory standards governing compounded testosterone depend on whether the medication comes from a 503A pharmacy or a 503B outsourcing facility. Congress established this framework under federal human drug compounding laws to differentiate local dispensing from larger manufacturing operations.
When a clinic orders compounded hormones, the safety standards depend on the facility classification. Traditional 503A pharmacies mix drugs for individual prescriptions and are exempt from Current Good Manufacturing Practice (CGMP) requirements. By contrast, registered 503B outsourcing facilities must comply with federal CGMP rules. The FDA inspects them on a risk-based schedule.
- 503A compounding pharmacies. These facilities are state-licensed and overseen by state boards of pharmacy. They compound medications for specific individual prescriptions and remain exempt from federal CGMP manufacturing standards.
- 503B outsourcing facilities. These entities register directly with the FDA and can produce batches without individual prescriptions. They must follow CGMP guidelines and undergo scheduled federal inspections.
Product Consistency and Adverse Event Tracking
Substandard compounding practices can cause serious drug quality failures, including bacterial contamination or incorrect active ingredient dosing. The FDA states that drugs containing too much or too little active hormone can cause severe patient harm or death. Commercial manufacturing requires strict batch testing to maintain uniform potency across every lot.
Adverse-event tracking reveals another difference between these options. Commercial manufacturers face mandatory legal requirements to report all adverse events to federal regulators. Compounding pharmacies historically had no comparable federal reporting obligation. Because of this gap, harm from a compounded preparation can go unrecorded.
An inspection of hormone pellet manufacturer BioTE Medical illustrates what happens without mandatory reporting. In a statement on adverse event reporting for compounded drugs, the FDA revealed that investigators uncovered 4,202 unreported adverse events during a 2018 inspection. Those records suggested a possible association between compounded hormone pellets and deep vein thrombosis, heart attacks, strokes, prostate cancer, endometrial cancer, cellulitis, and pellet extrusion.
What a Class-Wide Label Change Reaches
Federal labeling changes apply to FDA-approved testosterone products but do not alter documentation for compounded preparations. On February 28, 2025, the agency issued class-wide labeling changes for testosterone products following the completion of the TRAVERSE trial and required postmarket ambulatory blood-pressure studies.
The FDA instructed manufacturers of approved products to update their packaging information in five specific areas. First, sponsors added the TRAVERSE clinical trial results. Second, the FDA retained the Limitation of Use statement for age-related hypogonadism. Third, the agency removed the language in the Boxed Warning regarding an increased risk of adverse cardiovascular outcomes. Fourth, manufacturers added product-specific ambulatory blood-pressure data. Fifth, products that lacked a warning about increased blood pressure were required to add one.
These updates reached commercial testosterone packaging across the United States. However, compounded preparations have no FDA-reviewed label, so class-wide regulatory updates do not automatically reach compounded product paperwork. To stay informed, patients using compounded hormones can ask their prescribing physician to review current FDA-approved labeling at each clinical checkup.
Clinical Reasons for Compounded Formulations
Physicians prescribe compounded testosterone when a patient has specific physical needs that commercial products cannot accommodate. Some men have severe allergic reactions to the carrier oils used in commercial injections. A compounding pharmacist can prepare the same hormone in a different carrier oil for a patient with a documented allergy.
Compounding also allows prescribers to adjust drug concentrations or create alternative delivery formats. A doctor might request a customized topical cream concentration that is not commercially produced. Compounding pharmacies can also produce subcutaneous pellets for individuals who cannot tolerate injections or standard gels.
However, marketing claims surrounding custom formulations often exceed clinical evidence. The FDA has noted that some compounders market bioidentical hormone replacement therapy as superior, more natural, or safer than FDA-approved drugs. Commercial hormone products have undergone formal review for safety and effectiveness for specific medical uses. Compounded formulations have not received that evaluation. You can compare traditional and custom therapies in our guide to HRT vs bioidentical HRT.
Comparing Monthly Therapy Costs
The cost difference between brand-name and compounded testosterone sits primarily within transdermal options rather than across the entire treatment category. In our own published comparison of TRT delivery routes, checked September 2026, delivery method drives overall expense more than compounding status.
Testosterone injections of cypionate or enanthate cost roughly $30 to $100 a month for the drug. Transdermal gels and creams range from $40 to $300 monthly, where branded products and custom compounded formulations create varying out-of-pocket costs. Subcutaneous hormone pellets cost roughly $500 to $1,000 per insertion.
Our published ranges are drug costs, checked September 2026, and what a plan covers is a question for the plan. Readers exploring clinical programs can review our breakdown of longevity clinic costs.
Required Clinical Monitoring Protocols
Laboratory monitoring requirements are identical whether a patient takes commercial brand-name testosterone or a compounded preparation. Testosterone is classified as a Schedule III controlled substance under Drug Enforcement Administration (DEA) scheduling rules. That federal classification requires an active prescription from a registered healthcare provider for both product types.
Clinical safety guidelines apply equally across all formulations. The American Urological Association (AUA) testosterone deficiency guideline establishes clear diagnostic and safety monitoring protocols. The AUA guideline defines a hematocrit level of 54% or greater as the clinical threshold for polycythemia. Clinicians must measure hemoglobin and hematocrit at baseline and monitor those levels throughout treatment.
Testosterone increases red blood cell production regardless of manufacturing source. Unchecked hematocrit elevations raise blood viscosity and increase cardiovascular stress. Men receiving testosterone can learn about managing this complication in our guide to high hematocrit on TRT. For a broader overview of monitoring requirements, see our guide to the men's hormone panel.
Deciding Between Brand-Name and Compounded Options
Commercial products give you verified manufacturing controls. Compounded products give you a dose or a base that is not manufactured. Commercial products offer verifiable potency and strict facility oversight. They also carry mandatory adverse-event tracking. Compounded options provide formulation flexibility for patients with verified ingredient sensitivities or unusual dosage requirements.
Who should not choose compounded testosterone: Men with standard hypogonadism who have no allergies to commercial carrier oils have no medical need for compounded drugs. Commercial products offer proven manufacturing consistency and a lower drug cost. You can evaluate provider options in our review of the best TRT clinics.
What would change our answer: If federal regulators mandated CGMP compliance and compulsory adverse-event reporting for all 503A compounding pharmacies, the oversight gap would shrink. Until those regulatory changes occur, commercial formulations provide greater quality assurance.
Frequently Asked Questions
Is compounded testosterone FDA approved?
No, compounded testosterone is not approved by the Food and Drug Administration (FDA). The agency does not review compounded medications for safety, effectiveness, or manufacturing quality before they reach patients. Doctors can legally prescribe compounded preparations to meet specific individual requirements, such as an alternative carrier oil for an allergic patient. However, these custom formulations bypass the formal clinical trials and batch-testing requirements mandated for commercial brand-name pharmaceuticals.
Is compounded testosterone safe?
The FDA warns that poor compounding practices can cause product contamination or inconsistent hormone concentrations containing too much or too little active drug. During a 2018 inspection of BioTE Medical, federal investigators uncovered 4,202 adverse events that had never been reported to the agency, including strokes, blood clots, and infections. Safety depends heavily on whether the compounding facility follows strict quality controls.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
The primary difference is that 503B outsourcing facilities must comply with federal Current Good Manufacturing Practice (CGMP) standards, while 503A pharmacies are exempt. A 503A pharmacy prepares medications for individual patient prescriptions under the oversight of state boards of pharmacy. A 503B outsourcing facility registers directly with the FDA and undergoes risk-based federal inspections. Patients using compounded hormones receive greater manufacturing oversight when their prescription comes from a registered 503B facility.
Is compounded testosterone cheaper than brand-name testosterone?
Compounded testosterone is not universally less expensive than commercial brand-name or generic options. Monthly expenses depend primarily on the delivery method rather than whether a medication is compounded. In our published comparisons, injection therapies run roughly $30 to $100 monthly regardless of preparation type. Noticeable price gaps appear within transdermal creams and gels, where monthly costs range from $40 to $300 depending on branding.
Why do TRT clinics use compounded testosterone?
Clinicians prescribe compounded testosterone primarily to provide tailored dosages and alternative delivery formulations. Compounding pharmacies can produce customized topical creams, or subcutaneous pellets that commercial pharmaceutical companies do not manufacture. They can also formulate injections using alternative carrier oils for men with documented allergies. However, the FDA warns that marketing compounded hormones as inherently superior, more natural, or safer than approved commercial drugs is unsupported by clinical evidence.
Did the FDA change testosterone labels in 2025?
Yes, on February 28, 2025, the FDA announced class-wide labeling changes for approved testosterone products following the TRAVERSE trial. The agency instructed manufacturers to remove the Boxed Warning language regarding an increased risk of adverse cardiovascular outcomes. The update also added product-specific ambulatory blood-pressure data and a new warning regarding increased blood pressure. Because compounded testosterone lacks an FDA-reviewed label, these mandatory updates do not automatically alter paperwork for compounded preparations.
Do I still need blood work on compounded testosterone?
Yes, routine blood monitoring is necessary regardless of whether you take commercial brand-name testosterone or a compounded formulation. The American Urological Association guidelines state that clinicians must measure hemoglobin and hematocrit at baseline and monitor those levels during treatment. A hematocrit reading of 54% or higher marks the threshold for polycythemia, which thickens the blood. Both formulations raise red blood cell production, requiring regular laboratory testing to maintain patient safety.
Is compounded testosterone a controlled substance?
Yes, compounded testosterone is classified as a Schedule III controlled substance under DEA regulations. Controlled substance scheduling applies to the testosterone molecule itself. Neither the compounding process nor the absence of FDA approval alters federal drug scheduling. Prescriptions for both commercial brand-name products and compounded preparations require a DEA-registered prescriber.